Morfin Dak (Morphine Hydrochloride)

Morphine Hydrochloride, the active ingredient in Morfin Dak, is an opioid analgesic presented as an injectable solution for intravenous use. It provides potent relief of severe acute pain, post‑operative pain, and cancer‑related pain in adult patients requiring rapid onset analgesia.

GNH USA supplies Morfin Dak as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring consistent quality and regulatory compliance across global markets.

Morphine, an opioid analgesic, is used for managing pain that involves the central nervous system.

- Severe acute pain: provides rapid, strong analgesia to reduce pain intensity. - Post‑operative pain: controls pain after surgical procedures to facilitate recovery. - Cancer pain: alleviates persistent malignant pain in adult patients.

Morphine may cause a range of adverse reactions, varying from frequent to rare but serious.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation leading to a parched feeling. - Itching: mild pruritus, often localized. - Sweating: excessive perspiration without exertion.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Acute adrenal insufficiency: rare hormonal crisis requiring immediate care. - Anaphylaxis: severe allergic reaction with hives, swelling, and airway compromise. - Seizures: rare occurrence of convulsive episodes. - Cardiac arrest: sudden loss of heart function, extremely rare.

When using morphine injectable solutions, careful assessment and monitoring are essential to minimize risks. - Assess respiratory function: monitor breathing rate and depth before and during therapy. - Evaluate renal and hepatic function: adjust use in patients with impaired clearance. - Screen for opioid tolerance: consider prior opioid exposure to avoid overdose. - Avoid concurrent CNS depressants: limit use with benzodiazepines or alcohol. - Monitor for dependence: watch for signs of physical dependence or abuse. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Morphine injectable solution can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome. - Other opioids: additive CNS depression increasing overdose risk.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., alcohol, antihistamines): enhance sedative effects. - CYP3A4 inhibitors (e.g., ketoconazole): may increase morphine plasma levels. - Diuretics: can potentiate hypotensive effects. - Anticholinergics: may worsen constipation.